Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 3b study titled ‘A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab.’ This study aims to evaluate the safety and effectiveness of risankizumab versus vedolizumab in treating adults with moderate to severe ulcerative colitis who have not previously received targeted therapies. The study’s significance lies in its potential to offer new insights into treatment options for this inflammatory bowel disease.
The study tests two drugs: Risankizumab, administered initially via intravenous infusion and later as a subcutaneous injection, and Vedolizumab, given intravenously throughout. Both drugs are approved for moderate to severe ulcerative colitis and are being compared to determine their efficacy and safety in patients new to targeted therapies.
This interventional study is randomized with a parallel assignment model and no masking, focusing primarily on treatment. Participants are randomly allocated to receive either risankizumab or vedolizumab, with the primary purpose of assessing treatment efficacy.
The study began on June 17, 2025, and is currently recruiting participants. The primary completion and estimated study completion dates are yet to be announced. The latest update was submitted on August 5, 2025, indicating ongoing progress.
AbbVie’s study could influence its stock performance by potentially expanding its market share in the ulcerative colitis treatment space. Positive results may boost investor confidence, especially in comparison to competitors offering similar therapies. The study’s outcome could also impact the broader industry by setting new benchmarks for treatment efficacy and safety.
The study is ongoing, with further details available on the ClinicalTrials portal.